Tagged with Lilly

Saudi Arabia Having commenced his journey with American giant Lilly in 2008, and after almost eight years working in the company’s Japan organization, mostly on digital marketing, Dimitri Livadas crossed the Pacific Ocean to work in Lilly’s home market and the largest pharma market in the world, the United States, first in…

Saudi Arabia Clinical trials provide a pathway to innovation for clinicians and patients in countries like Saudi Arabia and form a key element of the country’s Vision 2030 national plan. As Saudi transitions away from oil towards becoming a knowledge-based economy, it is hoping to attract ever more international pharma companies to…

Saudi Arabia As part of Saudi Arabia’s ambitious ‘Vision 2030’ economic transformation plan, the country has centralised the public procurement of medications through the National Unified Procurement Company for Medical Supplies (NUPCO). Here, some of the Kingdom’s most prominent pharma leaders weigh in on the impact of this new system for their…

Saudi Arabia Lilly Saudi Arabia’s Dimitri Livadas shares some of the misconceptions he had before moving to the Kingdom a couple of years ago, highlights the evolution of the Saudi healthcare system with its current focus on digital health, the big opportunities for the Indiana-based company’s diabetes portfolio at a moment when…

India The latest from Indian pharma, including the year-to-year 51.5 percent growth of the pharma market in April, Lilly’s partnership with three generics makers to expand the availability of its arthritis drug baricitinib, Zydus Cadila’s upcoming approval of its COVID-19 vaccine, and the emergency use authorization for a COVID-19 antibody drug…

Coronavirus During the fourth International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) COVID-19 media briefing, one thematic dominated: collaboration. With Eli Lilly chairman and CEO David Ricks, also president of IFPMA; Roche CEO Dr Severin Schwan, also vice-president of IFPMA; Pfizer chairman and CEO Dr Albert Bourla; MSD (Merck & Co.…

China The partnership between global pharma giant Eli Lilly and Chinese biotech Innovent Biologics, first initiated in March 2015, continues to bear dividends for both parties. The recent announcement that Lillly has struck a deal for the exclusive license of Innovent’s TYVYT® drug outside of China stands to catapult the Chinese…

China Established in December 2012, in less than a decade, Chinese biotech Junshi Biosciences has already transformed itself into a publicly-listed commercial company with a successful USD 450 million IPO on the Hong Kong Stock Exchange and their first product, toripalimab, being the first anti-PD-1 monoclonal antibody self-developed by a Chinese…

Long Read Accounting for less than two percent of the global pharmaceutical market, the Middle East has long been somewhat overlooked by many drug makers, most of whom seemed more intent on chasing demand in the decidedly more populous Asian market space. But, with an estimated annual growth rate of 10 percent,…

Coronavirus During a global virtual press briefing on 19 March 2020, the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) gathered five global pharmaceutical leaders including Eli Lilly Chairman and CEO David A. Ricks, who is also the president of IFPMA for 2019-2020, to discuss the global ramifications of the COVID-19…

Coronavirus The CEOs and top executives, David Ricks, chairman and CEO, Eli Lilly & Co and IFPMA president, Severin Schwan, CEO, Roche, Paul Stoffels, chief scientific officer, Johnson & Johnson, David Loew, executive VP, Sanofi Pasteur and Rajeev Venkayya, president, Global Vaccines Business Unit, Takeda took part in a virtual press…

Romania Attila Fejer general manager of Eli Lilly in Romania gives his insights on the “deadly cocktail” of challenging policies that govern the pharmaceutical industry in the country. He shares the new therapeutic direction that Lilly has taken by moving into rheumatology and dermatology. Additionally, he points to the change in…